Ginkgo Bioworks (NYSE:DNA – Get Free Report) and Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.
Institutional and Insider Ownership
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Ginkgo Bioworks and Acumen Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ginkgo Bioworks | 3 | 1 | 1 | 0 | 1.60 |
| Acumen Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Profitability
This table compares Ginkgo Bioworks and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ginkgo Bioworks | -298.78% | -58.54% | -34.24% |
| Acumen Pharmaceuticals | N/A | -32.99% | -27.99% |
Valuation & Earnings
This table compares Ginkgo Bioworks and Acumen Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ginkgo Bioworks | $184.34 million | 1.92 | -$892.87 million | ($13.08) | -0.49 |
| Acumen Pharmaceuticals | N/A | N/A | -$52.37 million | ($1.38) | -1.74 |
Acumen Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Ginkgo Bioworks has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Summary
Acumen Pharmaceuticals beats Ginkgo Bioworks on 9 of the 14 factors compared between the two stocks.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
